Extremadura awards the supply of thermodynamic systems for €2.8 million

After reinforcing the electromedical equipment, Extremadura invests in thermodynamics. The regional government has awarded Edwards Lifesciences the supply of disposable advanced functional thermodynamic monitoring systems for $3.3 million (€2.8 million), according to the profile of the regional contractor. 

The U.S. company will have to supply the medical consumables to the Complejo Hospitalario Universitario de Badajoz and will be in charge of the supply for the next sixty months. The contract, despite being divided into two lots, has been won in its entirety by Edwards Lifesciences. The company will receive $1.9 million (€1.6 million) for the first package and $1.43 million (€1.2 million) for the second.  

Find more about Extremadura and read the most important news in the biotech sector with our companion app. The Born2Invest business news application is available for free for both Android and iOS devices.

With the implementation of advanced hemodynamic monitoring, the Executive expects to improve tissue oxygenation

The Regional Government of Extremadura argued that the contracting was “essential for the fulfillment and performance of the activities of the University Hospital Complex of Badajoz.” The functional thermodynamic monitoring systems are used in the specialties of anesthesiology and resuscitation and critical care. This consumable medical equipment allows adequate tissue perfusion that guarantees a correct supply of oxygen to the tissues, especially in medium-high risk patients, both in the preoperative period of the patients, to optimize their condition, and in the intraoperative and postoperative periods.

With the implementation of advanced hemodynamic monitoring, the Executive expects to improve tissue oxygenation and output, alleviate or prevent pulmonary abnormalities, evaluate cardiovascular function and response to therapy, evaluate pulmonary status and response to therapy, and evaluate fluid requirements in patients.  

Edwards Lifesciences has 14,000 employees and had revenues of $4.3 billion in 2019 

Edwards Lifesciences is a company specializing in medical innovations focused on the patient with structural heart disease, as well as critical care and surgical monitoring. The company was founded in 1958 and is led by Michael Mussallem, group CEO. 

The US company is headquartered in Irvine, California, and supplies medical products and technologies to nearly 100 countries. The company has 14,000 employees and recorded revenues of $4.3 billion in 2019. Just this March, Extremadura awarded GE Healthcare and Eulen the maintenance of electromedical equipment for $3 million (€2.6 million). Companies such as Althea Healthcare Spain, Ferrovial, Ibérica de Mantenimiento or Sainforan also participated in the bidding process.

The contract includes the comprehensive maintenance service of electromedical equipment for the health area of ​​Cáceres for a period of 24 months . An extension for a maximum of three years is contemplated. Equipment includes defibrillators, electrocardiographs, vital sign monitors, and critical parameter monitors. In addition to the joint venture between GE and Eulen, winners of the contract, other companies such as Althea Healthcare Spain, Ferrovial, Ibérica de Mantenimiento, Sainforan or the UTE TEC-SAN-Aocsa presented themselves to the bidding process. GE and Eulen have won the contest for presenting the “best offer in terms of quality and price,” the document reads.

__

(Featured image by RODNAEProductions via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.